70. Spinal stenosis Clinical trials / Disease details

Clinical trials : 96 /  Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05023733
(ClinicalTrials.gov)		October 1, 202116/8/2021Clinical and Radiographic Outcomes of TLIF w/3D Printed Cellular ImplantClinical and Radiographic Outcomes of Transforaminal Lumbar Interbody Fusion (TLIF) With a Novel 3D Printed Cellular Titanium ImplantForaminal Stenosis;Degenerative Disc Disease;Lumbar Spondylolisthesis;Lumbar Spinal StenosisDevice: CONDUIT™ Interbody Platform composed of the EIT (Emerging Implant Technologies) Cellular Titanium®Farhan KarimDePuy SynthesNot yet recruiting35 Years80 YearsAll150United States
2NCT03647501
(ClinicalTrials.gov)		August 22, 201821/8/2018Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody CagesLumbar Fusion With 3D-Printed Porous Titanium Interbody Cages - A Single-Blinded Randomized Controlled Trial Evaluating Nexxt Matrixx(TM) Versus PEEK CagesLumbar Degenerative Disc Disease;Lumbar Spinal Stenosis;Lumbar Spondylolisthesis;Lumbar Spinal Deformity;Lumbar SpondylosisDevice: Interbody cage (titanium);Device: Interbody cage (PEEK)Ohio State UniversityNexxt Spine, LLCRecruiting18 YearsN/AAll70N/AUnited States
3NCT03532945
(ClinicalTrials.gov)		October 28, 20102/5/2018A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody FusionA Long-term Follow-up Study to Evaluate the Efficacy and Safety for the Patients With Bioactive Glass-ceramic Intervertebral Spacer (Novomax) in Posterior Lumbar Interbody Fusion: Comparison With a Titanium CageDegenerative Lumbar Spinal StenosisDevice: Bioactive Glass-Ceramic Spacer;Device: Titanium cageBioAlpha Inc.NULLCompleted30 Years80 YearsAll62N/ANULL